On the other hand, genetic or pharmacological activation of KLF2 reversed multiple aspects of the induced endothelial dysfunction thus proposing KLF2 activation as a plausible strategy to improve COVID-19 associated endothelial dysfunction [99]. This evidence concerns the gene KLF2 and endothelial dysfunction.